首页> 外文OA文献 >μO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits
【2h】

μO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits

机译:μO-芋螺毒素MrVIB选择性阻断Nav1.8感觉神经元特异的钠通道和慢性疼痛行为而无运动功能障碍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The tetrodotoxin-resistant voltage-gated sodium channel (VGSC) Nav1.8 is expressed predominantly by damage-sensing primary afferent nerves and is important for the development and maintenance of persistent pain states. Here we demonstrate that μO-conotoxin MrVIB from Conus marmoreus displays substantial selectivity for Nav1.8 and inhibits pain behavior in models of persistent pain. In rat sensory neurons, submicromolar concentrations of MrVIB blocked tetrodotoxin-resistant current characteristic of Nav1.8 but not Nav1.9 or tetrodotoxin-sensitive VGSC currents. MrVIB blocked human Nav1.8 expressed in Xenopus oocytes with selectivity at least 10-fold greater than other VGSCs. In neuropathic and chronic inflammatory pain models, allodynia and hyperalgesia were both reduced by intrathecal infusion of MrVIB (0.03–3 nmol), whereas motor side effects occurred only at 30-fold higher doses. In contrast, the nonselective VGSC blocker lignocaine displayed no selectivity for allodynia and hyperalgesia versus motor side effects. The actions of MrVIB reveal that VGSC antagonists displaying selectivity toward Nav1.8 can alleviate chronic pain behavior with a greater therapeutic index than nonselective antagonists.
机译:耐河豚毒素的电压门控钠通道(VGSC)Nav1.8主要由损伤敏感的初级传入神经表达,对于持续性疼痛状态的发展和维持非常重要。在这里,我们证明了来自Conus marmoreus的μO-芋螺毒素MrVIB对Nav1.8显示出实质性的选择性,并在持续性疼痛模型中抑制了疼痛行为。在大鼠感觉神经元中,亚微摩尔浓度的MrVIB阻断了Nav1.8的河豚毒素抗性电流特性,但没有阻断Nav1.9或河豚毒素敏感的VGSC电流。 MrVIB阻断在非洲爪蟾卵母细胞中表达的人Nav1.8,选择性比其他VGSC高至少10倍。在神经性和慢性炎性疼痛模型中,鞘内注射MrVIB(0.03–3 nmol)可以减轻异常性疼痛和痛觉过敏,而运动副作用仅在高剂量30倍时发生。相比之下,非选择性VGSC阻滞剂利格卡因与运动副作用相比,对痛觉过敏和痛觉过敏没有选择性。 MrVIB的作用表明,对Nav1.8具有选择性的VGSC拮抗剂比非选择性拮抗剂具有更大的治疗指数,可减轻慢性疼痛行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号